✨
AI Summary
- PepGen's Dr. Michelle Mellion discusses delivering oligonucleotide therapies for neuromuscular diseases.
- The company is trialing PGN-EDO51 for DMD patients amenable to exon 51 skipping.
- Focus is on overcoming delivery challenges for these advanced therapeutic approaches.
Guests on This Episode
MM
Michelle Mellion
1 podcast appearance